

Bristol Myers Squibb

Compendium of presentations



This booklet may represent investigational, unapproved uses of some products listed. The safety and efficacy of investigational agents and/or investigational uses or combinations of agents approved for other indications have not been established. There is no guarantee that investigational agents or regimens will receive health authority approval or become commercially available in any country for the uses being investigated. This compilation of presentations is intended as an educational resource and is for the exchange of scientific data with clinical investigators and healthcare professionals.

Click on date to see a list of scheduled presentations; click on a therapeutic area to go directly to those presentations.

Table of Contents

Saturday, December 11

[Multiple Myeloma ▶](#)

[Lymphoma ▶](#)

[Leukemia ▶](#)

[Thalassemia ▶](#)

[Myelofibrosis ▶](#)

[Myelodysplastic Syndromes ▶](#)

[Other ▶](#)

Sunday, December 12

[Multiple Myeloma ▶](#)

[Lymphoma ▶](#)

[Leukemia ▶](#)

[Thalassemia ▶](#)

[Myelofibrosis ▶](#)

Monday, December 13

[Lymphoma ▶](#)

[Leukemia ▶](#)

[Thalassemia ▶](#)

[Myelofibrosis ▶](#)

[Myelodysplastic Syndromes ▶](#)

[Other ▶](#)

Saturday, December 11

MULTIPLE MYELOMA

Oral Presentations

Presentation #117: Real-world treatment patterns and clinical, economic, and humanistic burden in triple class refractory multiple myeloma: analysis of the CONNECT multiple myeloma (MM) disease registry

Lead Author and Presenter: Derek Tang, Sundar Jagannath*; Bristol Myers Squibb, Princeton, NJ, USA

Session: Outcomes research–lymphoid malignancies: multiple myeloma and other plasma cell disorders

Presentation #162: Iberdomide (IBER) in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the dose-expansion phase of the CC-220-MM-001 trial

Lead Author and Presenter: Sagar Lonial, Emory University, Atlanta, GA, USA

Session: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: novel targets and amyloid

Poster Presentations

Presentation #1613: Pre-clinical and clinical immunomodulatory effects of pomalidomide or CC-92480 in combination with bortezomib in multiple myeloma

Lead Author and Presenter: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster I

Presentation #1662: Impact of elotuzumab plus pomalidomide/dexamethasone on health-related quality of life for patients with relapsed/refractory multiple myeloma (RRMM): final data from the phase 2 ELOQUENT-3 trial

Lead Author and Presenter: Katja Weisel, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany

Session: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster I

Presentation #1739: Baseline correlates of complete response to idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy in patients with relapsed and refractory multiple myeloma: subanalysis of the KarMMa trial

Lead Author and Presenter: Nina Shah, University of California San Francisco, San Francisco, CA, USA

Session: Cellular immunotherapies: clinical: poster I

*Presenter differs from lead author

Poster Presentations

Presentation #1978: Matching-adjusted indirect comparisons of efficacy outcomes in patients with relapsed and refractory multiple myeloma for idecabtagene vicleucel (KarMMa) versus selinexor plus dexamethasone (STORM part 2) and belantamab mafodotin (DREAMM-2): updated analysis with longer follow-up

Lead Author and Presenter: Paula Rodriguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

Session: Outcomes research—lymphoid malignancies: poster I

LYMPHOMA

Oral Presentation

Presentation #91: Lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, versus standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the randomized phase 3 TRANSFORM study

Lead Author and Presenter: Manali Kamdar, University of Colorado Cancer Center, Denver, CO, USA

Session: Cellular immunotherapies: cellular therapies for lymphomas

Accepted for ASH Annual Meeting Press Program

Poster Presentations

Presentation #1200: CC-99282 is a novel cereblon (CRBN) E3 ligase modulator (CELMoD) agent with enhanced tumoricidal activity in preclinical models of lymphoma

Lead Author and Presenter: Soraya Carrancio, Bristol Myers Squibb, Princeton, NJ, USA

Session: Molecular pharmacology and drug resistance: lymphoid neoplasms: poster I

Presentation #1460: CONNECT[®] lymphoma disease registry: a US-based, prospective, observational cohort study

Lead Author and Presenter: Christopher Flowers, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Aggressive lymphomas: clinical and epidemiological: poster I

Presentation #1762: Outreach: results from a phase 2 study of lisocabtagene maraleucel (liso-cel) administered as inpatient (Inpt) or outpatient (Outpt) treatment in the nonuniversity setting in patients (pts) with R/R large B-cell lymphoma (LBCL)

Lead Author and Presenter: John Godwin, Earle A. Chiles Research Institute, Portland, OR, USA

Session: Cellular immunotherapies: clinical: poster I

LEUKEMIA

Oral Presentations

Presentation #277: Real-world evidence comparing venetoclax plus azacitidine (VEN-AZA) vs. intensive chemotherapy (IC) as induction for patients with acute myeloid leukemia (AML): retrospective analysis of an electronic medical records database in the United States

Lead Author and Presenter: Amer Zeidan, Yale University, New Haven, CT, USA

Session: Outcomes research—myeloid malignancies: real world outcomes

Presentation #279: Treatment patterns and survival outcomes of patients with acute myeloid leukemia who achieved remission in the CONNECT myeloid disease registry

Lead Author and Presenter: Gail Roboz, Weill Cornell Medicine and New York Presbyterian Hospital, New York, NY, USA

Session: Outcomes research—myeloid malignancies: real world outcomes

Poster Presentations

Presentation #1243: Outcomes for patients with late-stage mutant-IDH2 (mIDH2) relapsed/refractory acute myeloid leukemia (R/R AML) treated with enasidenib vs other lower-intensity therapies in the randomized, phase 3 IDHentify trial

Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster I

Presentation #1244: Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (mIDH2) acute myeloid leukemia (AML) not eligible for intensive chemotherapy (IC)

Lead Author and Presenter: Courtney DiNardo, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster I

β THALASSEMIA

Poster Presentation

Presentation #1955: Systematic literature review of the indirect costs, humanistic burden, patient or caregiver preference, and qualitative outcomes in beta-thalassemia

Lead Author and Presenter: Yesim Aydinok, Ege University, Izmir, Turkey

Session: Outcomes research—non-malignant conditions: poster I

MYELOFIBROSIS

Poster Presentations

Presentation #1490: A phase 3 study of efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring red blood cell transfusions

Lead Author and Presenter: Ruben Mesa, UT Health San Antonio Cancer Center, San Antonio, TX, USA

Session: Myeloproliferative syndromes: clinical and epidemiological: poster I

Presentation #1980: Clinical outcomes at 3 and 6 months of fedratinib therapy following prior ruxolitinib failure: real-world assessment of spleen, symptoms, and hematologic response

Lead Author and Presenter: John Mascarenhas, Icahn School of Medicine at Mount Sinai, New York, NY, USA

Session: Outcomes research—myeloid malignancies: poster I

MYELOYDYSPLASTIC SYNDROMES

Poster Presentation

Presentation #1524: Analysis of duration of response, exposure-adjusted safety and progression to acute myeloid leukemia (AML) for patients with lower-risk myelodysplastic syndromes (LR-MDS) receiving luspatercept in the MEDALIST study

Lead Author and Presenter: Uwe Platzbecker, University Hospital Leipzig, Leipzig, Germany

Session: Myelodysplastic syndromes—clinical and epidemiological: poster I

OTHER

Poster Presentation

Presentation #1951: Discordance between treatment guideline recommendations and real-world practice in a group of large integrated delivery networks for venous thromboembolism (VTE) patients: a closer look at VTE patients with cancer

Lead Author and Presenter: Juzer Lotya, Amol Dhamane*; IQVIA Inc., Dublin, Ireland and Bristol Myers Squibb, Princeton, NJ, USA

Session: Outcomes research—non-malignant conditions: poster I

Sunday, December 12

MULTIPLE MYELOMA

Oral Presentation

Presentation #548: Updated clinical and correlative results from the phase I CRB-402 study of the BCMA-targeted CAR-T cell therapy bb21217 in patients with relapsed and refractory multiple myeloma

Lead Author and Presenter: Noopur Raje, Massachusetts General Hospital, Boston, MA, USA

Session: Cellular immunotherapies: cellular therapies for myeloma

Poster Presentations

Presentation #2658: Super-enhancer driven regulation of CKS1B in multiple myeloma: implications in mediating response to BET inhibitor and CELMoD agent combination

Lead Author and Presenter: Aarif Ahsan, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II

Presentation #2669: CC-92480 enhances cell-autonomous cytotoxicity through blockade of G2/M transition when combined with bortezomib/dexamethasone in pre-clinical multiple myeloma

Lead Author and Presenter: Chad Bjorklund, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II

*Presenter differs from lead author

Poster Presentations

Presentation #2681: Location of the t(4;14) translocation breakpoint identifies a subset of newly-diagnosed multiple myeloma patients with poor prognosis

Lead Author and Presenter: Nicholas Stong, Bristol Myers Squibb, Princeton, NJ, USA

Session: Multiple myeloma and plasma cell dyscrasias: basic and translational: poster II

Presentation #2731: CC-92480, a potent, novel cereblon E3 ligase modulator (CELMoD) agent, in combination with dexamethasone (DEX) and bortezomib (BORT) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): preliminary results from the phase 1/2 study CC-92480-MM-002

Lead Author and Presenter: Paul Richardson, Dana-Farber Cancer Institute, Boston, MA, USA

Session: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster II

Presentation #2743: Subsequent anti-myeloma therapy after idecabtagene vicleucef (Ide-cel, bb2121) treatment in patients with relapsed/refractory multiple myeloma from the KarMMa study

Lead Author and Presenter: Paula Rodriguez-Otero, Clínica Universidad de Navarra, Pamplona, Spain

Session: Myeloma and plasma cell dyscrasias: clinical-prospective therapeutic trials: poster II

Presentation #2835: Updated health-related quality of life results from the KarMMa clinical study in patients with relapsed and refractory multiple myeloma treated with the B-cell maturation antigen-directed chimeric antigen receptor T cell therapy idecabtagene vicleucef (ide-cel, bb2121)

Lead Author and Presenter: Michel Delforge, University Hospital Leuven, Leuven, Belgium

Session: Cellular immunotherapies: clinical: poster II

Presentation #3041: Idecabtagene vicleucef (ide-cel, bb2121), a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy: qualitative analyses of post-treatment interviews (months 6–24) for patients with relapsed and refractory multiple myeloma in the KarMMa clinical trial

Lead Author and Presenter: Nina Shah, University of California San Francisco, San Francisco, CA, USA

Session: Outcomes research—lymphoid malignancies: poster II

LYMPHOMA

Poster Presentations

Presentation #2271: Discovery and preclinical characterization of CC 95251, an anti-Sirp α antibody that enhances macrophage-mediated phagocytosis of non-Hodgkin lymphoma (NHL) cells when combined with rituximab

Lead Author and Presenter: Henry Chan, Bristol Myers Squibb, Princeton, NJ, USA

Session: Molecular pharmacology and drug resistance: lymphoid neoplasms: poster II

Presentation #2454: Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine (AN+AD) for advanced stage classic Hodgkin lymphoma: preliminary safety results from the single-arm phase 2 study (SGN35-027 part B)

Lead Author and Presenter: Hun Ju Lee, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Hodgkin lymphomas and T/NK cell lymphomas: clinical and epidemiological: poster II

Presentation #2493: Interim results from the first clinical study of CC-95251, an anti-signal regulatory protein-alpha (SIRP α) antibody, in combination with rituximab in patients with relapsed and/or refractory non-Hodgkin lymphoma (R/R NHL)

Lead Author and Presenter: Paolo Strati, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Aggressive lymphomas: prospective therapeutic trials: poster II

Presentation #2840: Two-year follow-up of TRANSCEND NHL 001, a multicenter phase 1 study of lisocabtagene maraleucel (liso-cel) in relapsed or refractory (R/R) large B-cell lymphomas (LBCL)

Lead Author and Presenter: Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Session: Cellular immunotherapies: clinical: poster II

Presentation #3003: Cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) for treatment of relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Lead Author and Presenter: Christopher Parker, Bristol Myers Squibb, Uxbridge, United Kingdom

Session: Health services research—lymphoid malignancies: poster II

LEUKEMIA

Poster Presentations

Presentation #2314: OMNIVERSE: a phase 1b study of oral azacitidine plus venetoclax in patients with relapsed/refractory (R/R) or newly diagnosed (ND) acute myeloid leukemia (AML)

Lead Author and Presenter: Farhad Ravandi, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Session: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: poster II

Presentation #3015: Matching adjusted indirect comparison (MAIC) of oral azacitidine (AZA) versus injectable AZA in patients (pts) with acute myeloid leukemia (AML) in first remission after intensive induction chemotherapy

Lead Author and Presenter: Clara Chen, Bristol Myers Squibb, Princeton, NJ, USA

Session: Health services research—myeloid malignancies: poster II

β THALASSEMIA

Poster Presentation

Presentation #2984: Modeling the future blood requirements in patients with transfusion-dependent β-thalassemia in Greece

Lead Author and Presenter: Kyriakos Souliotis, Maria Tsironi*; University of Peloponnese, Tripoli, Greece

Session: Health services research—non-malignant conditions: poster II

MYELOFIBROSIS

Oral Presentation

Presentation #389: Safety and tolerability of fedratinib (FEDR), an oral inhibitor of Janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

Lead Author and Presenter: Vikas Gupta, Princess Margaret Cancer Centre, Toronto, ON, Canada

Session: Myeloproliferative syndromes: clinical and epidemiological: novel therapies for MPNs and JAK inhibitors for myelofibrosis

*Presenter differs from lead author

Poster Presentations

Presentation #2576: Spleen and symptom responses with fedratinib (FEDR) in patients with myelofibrosis (MF) and substantial splenomegaly

Lead Author and Presenter: Jean-Jacques Kiladjian, Hôpital Saint-Louis; Université de Paris, INSERM, Paris, France

Session: Myeloproliferative syndromes: clinical and epidemiological: poster II

Presentation #3059: Real-world utilization of fedratinib for myelofibrosis post-ruxolitinib: patient characteristics, treatment patterns, and characterization of ruxolitinib failure

Lead Author and Presenter: Claire Harrison, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

Session: Outcomes research—myeloid malignancies: poster II

Monday, December 13

LYMPHOMA

Oral Presentation

Presentation #812: Completed induction phase analysis of MAGNIFY: phase 3b study of lenalidomide + rituximab (R2) followed by maintenance in relapsed/refractory indolent non-Hodgkin lymphoma

Lead Author and Presenter: Frederick Lansigan, Dartmouth–Hitchcock Medical Center, Lebanon, NH, USA

Session: Mantle cell, follicular, and other B-cell lymphomas: clinical and epidemiological: follicular lymphoma: advances in treatment approaches

Poster Presentations

Presentation #3574: Clinical activity of CC-99282, a novel, oral small molecule cereblon E3 ligase modulator (CELMoD) agent, in patients (pts) with relapsed or refractory non-Hodgkin lymphoma (R/R NHL) – first results from a phase 1, open-label study

Lead Author and Presenter: Jean-Marie Michot, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy Institute of Cancer, Villejuif, France

Session: Aggressive lymphomas: prospective therapeutic trials: poster III

Poster Presentations

Presentation #3834: Characteristics of post-infusion chimeric antigen receptor (CAR) T cells and endogenous T cells associated with early and long-term response in lisocabtagene maraleucel (liso-cel)–treated relapsed or refractory (R/R) large B-cell lymphoma (LBCL)

Lead Author and Presenter: Jerill Thorpe, Bristol Myers Squibb, Princeton, NJ, USA

Session: Cellular immunotherapies: clinical: poster III

Presentation #3845: Improved quality of life (QOL) with lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, compared with standard of care (SOC) as second-line (2L) treatment in patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL): results from the phase 3 TRANSFORM study

Lead Author and Presenter: Jeremy Abramson, Massachusetts General Hospital Cancer Center, Boston, MA, USA

Session: Cellular immunotherapies: clinical: poster III

Presentation #4098: Interviews of patients (pts) with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) enrolled in 2 lisocabtagene maraleucel (liso-cel) trials on their treatment experience for 3 months after infusion

Lead Author and Presenter: Tanya Siddiqi, City of Hope National Medical Center, Duarte, CA, USA

Session: Outcomes research—lymphoid malignancies: poster III

LEUKEMIA

Oral Presentations

Presentation #804: Prognostic impact of NPM1 and FLT3 mutations at diagnosis and presence of measurable residual disease (MRD) after intensive chemotherapy (IC) for patients with acute myeloid leukemia (AML) in remission: outcomes from the Quazar AML-001 trial of oral azacitidine (oral-AZA) maintenance

Lead Author and Presenter: Hartmut Döhner, Ulm University Hospital, Ulm, Germany

Session: Acute myeloid leukemias: biomarkers, molecular markers and minimal residual disease in diagnosis and prognosis: new options of risk assessment and prediction of therapy response in AML

Presentation #871: Long-term overall survival (OS) with oral azacitidine (oral-AZA) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (IC): updated results from the phase 3 Quazar AML-001 trial

Lead Author and Presenter: Andrew H. Wei, The Alfred Hospital, Melbourne, Australia

Session: Acute myeloid leukemias: commercially available therapies, excluding transplantation and cellular immunotherapies: updates in treatment for high-risk AML

Poster Presentations

Presentation #3330: Synergistic combination activity of the novel GSPT1 degrader CC-90009 in acute myeloid leukemia models

Lead Author and Presenter: Daniel Pierce, Bristol Myers Squibb, Princeton, NJ, USA

Session: Molecular pharmacology and drug resistance: myeloid neoplasms: poster III

Presentation #3355: Low exposure extended dosing mimicking clinical exposures of the oral formulation of azacitidine results in a sustained hypomethylation and targets leukemic stem cells

Lead Author and Presenter: Danny Jeyaraju, Bristol Myers Squibb, Princeton, NJ, USA

Session: Molecular pharmacology and drug resistance: myeloid neoplasms: poster III

Presentation #3607: Dasatinib treatment patterns after pleural effusion among patients diagnosed with chronic myeloid leukemia

Lead Author and Presenter: John Brokars, Bristol Myers Squibb, Princeton, NJ, USA

Session: Chronic myeloid leukemia: clinical and epidemiological: poster III

Presentation #4039: Healthcare resource utilization and costs in US patients with newly diagnosed acute myeloid leukemia treated with intensive induction chemotherapy

Lead Author and Presenter: David Huggar, Thomas W. LeBlanc*; Bristol Myers Squibb, Princeton, NJ, USA and Duke University School of Medicine, Durham, NC, USA

Session: Health services research—myeloid malignancies: poster III

Presentation #4139: The impact of COVID-19 on acute myeloid leukemia (AML) treatment patterns in the United States: retrospective analysis of an electronic medical records (EMR) database

Lead Author and Presenter: Clara Chen, Bristol Myers Squibb, Princeton, NJ, USA

Session: Outcomes research—myeloid malignancies: poster III

Presentation #4140: Impact of post-remission maintenance therapy (MT) on outcomes in patients (pts) with newly diagnosed acute myeloid leukemia (AML) in real-world practice

Lead Author and Presenter: Ravi Potluri, SmartAnalyst Inc., New York, NY, USA

Session: Outcomes research—myeloid malignancies: poster III

*Presenter differs from lead author

β THALASSEMIA

Oral Presentation

Presentation #761: Luspatercept redistributes body iron to the liver in transfusion-dependent-thalassemia (TDT) during erythropoietic response

Lead Author and Presenter: Maciej Garbowski, University College London Hospitals, London, United Kingdom

Session: Iron homeostasis and biology: disorders of iron and heme and novel treatments

Poster Presentations

Presentation #3081: Luspatercept improves quality of life and reduces red blood cell transfusion burden in patients with non-transfusion-dependent β thalassemia in the BEYOND trial

Lead Author and Presenter: Antonis Kattamis, National and Kapodistrian University of Athens, Athens, Greece

Session: Thalassemia and globin gene regulation: poster III

Presentation #4062: Understanding the association between red blood cell transfusion dependency and humanistic, psychosocial, and psychological burden in patients with β-thalassemia from the patients' perspective

Lead Author and Presenter: Kwanza Price, Bristol Myers Squibb, Princeton, NJ, USA

Session: Outcomes research—non-malignant conditions: poster III

MYELOFIBROSIS

Poster Presentations

Presentation #3643: A randomized, phase 3 trial of fedratinib versus best available therapy in patients with intermediate-2 or high-risk myelofibrosis previously treated with ruxolitinib (FREEDOM2)

Lead Author and Presenter: Nicola Vianelli, Francesco Passamonti*; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy and University of Insubria and ASST Sette Laghi, Varese, Italy

Session: Myeloproliferative syndromes: clinical and epidemiological: poster III

Presentation #3645: Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis

Lead Author and Presenter: Francesco Passamonti, University of Insubria and ASST Sette Laghi, Varese, Italy

Session: Myeloproliferative syndromes: clinical and epidemiological: poster III

*Presenter differs from lead author

MYELODYSPLASTIC SYNDROMES

Poster Presentation

Presentation #3686: Treatment patterns and outcomes of patients with lower-risk myelodysplastic syndromes in the CONNECT myeloid disease registry

Lead Author and Presenter: Rami S. Komrokji, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

Session: Myelodysplastic syndromes—clinical and epidemiological: poster III

OTHER

Oral Presentation

Presentation #670: Anticoagulant treatment patterns and outcomes in patients with venous thromboembolism and active cancer – a nationwide cohort study in France

Lead Author and Presenter: Laurent Bertoletti, CHU de St-Etienne, Université Jean-Monnet, St-Etienne, France

Session: Anticoagulation and antithrombotic therapies

Poster Presentation

Presentation #3912: Improved overall survival of patients treated with abatacept in combination with a calcineurin inhibitor and methotrexate following 7/8 HLA-matched unrelated allogeneic hematopoietic stem cell transplantation: analysis of the Center for International Blood and Marrow Transplant Research database

Lead Author and Presenter: Leslie Kean, Dana-Farber Cancer Institute, Boston, MA, USA

Session: Allogeneic transplantation: acute and chronic GVHD, immune reconstitution: poster III